Search the Newsreel

HC Wainwright Analysts Lower Earnings Estimates for RNAC

Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cartesian Therapeutics Advances RNA Cell Therapy Pipeline; Wedbush Sets $38 Price Target

Cartesian Therapeutics (RNAC) is advancing its RNA cell therapy pipeline, with its lead candidate, Descartes-08, an autologous RNA CAR-T therapy, holding significant potential for autoimmune diseases. Wedbush has set a price target of $38 for the company. The therapy has received FDA RMAT, Fast …

Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results

Cartesian Therapeutics (NASDAQ:RNAC) announced its quarterly earnings, reporting an EPS of $0.46, significantly beating the consensus estimate of a $0.88 loss. Following the announcement, RNAC shares rose 1.0% to $8.85, with analysts maintaining a "Moderate Buy" rating and an average price target of $32.60. …

A Quick Look at Today's Ratings for Cartesian Therapeutics(RNAC.US), With a Forecast Between $25 to $44

This article provides an overview of recent analyst ratings for Cartesian Therapeutics (RNAC.US), highlighting a price target forecast ranging from $25 to $44. It indicates that the company has received a "Strong Buy" consensus from analysts, based on positive evaluations over the past three …

Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating

Cartesian Therapeutics (NASDAQ:RNAC) was upgraded by Wall Street Zen from a "sell" to a "hold" rating. Despite this upgrade, the company still holds a "Moderate Buy" consensus rating among analysts with an average price target of $32.60. Institutional investors own a significant portion of …

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. announced the granting of inducement awards to four new employees, consisting of options to purchase 115,250 shares of the Company’s common stock. These options have an exercise price equal to the closing trading price on their respective grant dates of August …

Four new employees get options for 115,250 Cartesian shares

Cartesian Therapeutics (NASDAQ: RNAC) has granted stock options for an aggregate of 115,250 common shares to four new employees, with grant dates of August 3 and August 6, 2026. These options have an exercise price equal to the closing Nasdaq Global Market price on …

Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC

Cartesian Therapeutics reported research and development expenses of $20.4 million for the second quarter. This financial detail is a key indicator of the company's investment in its pipeline and future growth. The article focuses solely on this financial reporting without further elaboration.

Cartesian Therapeutics Inc (RNAC) Stock News Today

Cartesian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Cartesian Therapeutics, Inc. announced its financial results for the second quarter and six months ended June 30, 2026. For the second quarter, the company reported a net income of $15.77 million. However, for the six-month period, the company posted a net loss of $23.41 …

Cartesian Therapeutics Q2 2026 earnings: R&D spending rises as Phase 3 advances

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2026 revenue of $0, with a diluted EPS of $0.46. The company experienced an increase in R&D spending due to the advancement of its Phase 3 AURORA trial, which widened its operating loss. However, a significant fair-value gain …

Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership

Cartesian Therapeutics announced significant progress in its clinical trials for Descartes-08, a cell therapy for autoimmune diseases, including the Phase 3 AURORA trial for myasthenia gravis and Phase 2 TRITON trial for myositis, with data expected in Q1 and H1 2027, respectively. The company …

Cartesian Therapeutics reports Q2 2026: $149.3M cash; net income $15.8M; Phase 3 MG data expected 1Q27

Cartesian Therapeutics reported its Q2 2026 financial results, including $149.3 million in cash and a net income of $15.8 million. The company announced that its Phase 3 AURORA trial for Descartes-08 in myasthenia gravis is on track, with data expected in Q1 2027 and …

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical pipeline and an extended cash runway into 2028. Key advancements include the Phase 3 AURORA trial for myasthenia gravis, a new strategic partnership with WestGene for an in vivo CAR-T …

Cartesian Therapeutics (Nasdaq: RNAC) Q2 earnings boosted by CVR revaluation

Enterprise value to revenue forward of Cartesian Therapeutics, Inc. – MUN:1S70

The article focuses on the enterprise value to revenue forward metric for Cartesian Therapeutics, Inc. (MUN:1S70), listed on the Munich Stock Exchange. It provides financial overview, documents, news, community insights, forecasts, seasonals, and ETF information related to the company. The content appears to be …

Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Cartesian Therapeutics Inc is anticipated to report a loss of 87 cents per share. This earnings preview is based on information from Refinitiv and was published by Reuters. The full article can be accessed on TradingView for subscribers.

Price to sales forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC

This article focuses on the "Price to sales forward" financial metric for Cartesian Therapeutics, Inc. (NASDAQ: RNAC). It appears to be a financial data page from TradingView, providing an overview of the company's stock information and financial figures.

RNAC|Cartesian Therapeutics Inc|Price:7.800|Chg%:+0.070

Cartesian Therapeutics Inc (RNAC) is a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, with its lead asset, Descartes-08, entering Phase 3 trials. The stock is currently rated a "Buy" by analysts with a target price of $33.83, indicating significant upside potential. …

Cartesian Therapeutics Inc (RNAC) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Cartesian Therapeutics Inc (RNAC), noting its current valuation score is 6.20, ranking it 328 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.35 and mentions that relevant …

Cartesian Therapeutics Inc (RNAC) Institutional Confidence

Cartesian Therapeutics Inc (RNAC) has an institutional shareholding score of 3.00, placing it 191st out of 384 in its industry. The institutional shareholding proportion increased by 9.60% quarter-over-quarter to 27.21%. James Simons is noted as the largest institutional shareholder, though the article also lists …

Cartesian Therapeutics Inc (RNAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cartesian Therapeutics Inc (RNAC), detailing its stock price momentum, support and resistance levels, and various technical indicators. It shows the stock currently has a price momentum score of 5.02 and is trading between a resistance of $9.93 …

Cartesian Therapeutics Inc (RNAC) Financial Health: Profitability & Balance Sheet Analysis

Cartesian Therapeutics Inc (RNAC) currently holds a financial score of 5.47, ranking 355 out of 386 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The company reported a significant year-over-year decrease of 92.91% in its latest …

Cartesian Therapeutics Inc (RNAC) Cash Flow

This article provides a detailed historical cash flow statement for Cartesian Therapeutics Inc (RNAC), presenting quarterly and annual figures for operating, investing, and financing activities. It also includes frequently asked questions defining various cash flow metrics and detailing RNAC's specific amounts for operating cash …

Cartesian Therapeutics, Inc. Revenue Breakdown – FWB:1S70

Cartesian Therapeutics, Inc. (FWB:1S70) generated 2.38 million EUR in revenue last year, primarily from its Nanoparticle Immunomodulatory Drugs segment. This marks a significant decrease from the 37.59 million EUR earned the previous year, with all revenue originating from the United States. The article provides …

Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides an overview of Cartesian Therapeutics Inc (RNAC), detailing its current stock price and market capitalization. However, it explicitly states that relevant data regarding the company's revenue breakdown by business segment and region, as well as profit contribution, have not …

Cartesian Therapeutics Inc (RNAC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Cartesian Therapeutics Inc (RNAC)'s dividend history and stock split events. It indicates that the company has not distributed dividends in the past five years and lists multiple merger-related stock split events on March 28, 2024, at a 30→1 ratio.

RNAC|Cartesian Therapeutics Inc|Price:8.690|Chg%:-0.160

Cartesian Therapeutics Inc. (RNAC) is a clinical-stage company focused on cell therapy for autoimmune diseases, utilizing its proprietary technology to enhance cell function with mRNA molecules. Their lead asset, Descartes-08, a CAR-T therapy, is in Phase 3 clinical development for generalized myasthenia gravis and …

Cartesian Therapeutics Inc (RNAC) Risk Assessment: Volatility, Financial Risk & Investment Risk

RNAC|Cartesian Therapeutics Inc|Price:7.780|Chg%:-0.100

Cartesian Therapeutics Inc. (RNAC) is a clinical-stage company focused on cell therapy for autoimmune diseases, utilizing its proprietary technology to enhance cell function with mRNA molecules. Their lead asset, Descartes-08, a CAR-T therapy, is in Phase 3 clinical development for generalized myasthenia gravis and …

TradingKey

This article provides a detailed income statement for Cartesian Therapeutics Inc. (RNAC) data from Q1 FY2015 to Q1 FY2026. The financial data includes total revenue, operating expenses, R&D expenses, operating profit, net income, and basic and diluted earnings per share, along with year-over-year percentage …

ETFs Investing in Cartesian Therapeutics, Inc. Stocks

This article lists ETFs that invest in Cartesian Therapeutics, Inc. stocks, providing details such as market value, weight, issuer, management style, and expense ratio. It highlights three specific ETFs: Janus Henderson Small Cap Growth Alpha ETF (JSML), iShares Microcap ETF (IWC), and Invesco NASDAQ …